Boston Family Office LLC Sells 1,017 Shares of Becton, Dickinson and Company (NYSE:BDX)

Boston Family Office LLC decreased its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 15.3% in the 4th quarter, Holdings Channel reports. The firm owned 5,647 shares of the medical instruments supplier’s stock after selling 1,017 shares during the quarter. Boston Family Office LLC’s holdings in Becton, Dickinson and Company were worth $1,281,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of BDX. Bank of Jackson Hole Trust bought a new stake in shares of Becton, Dickinson and Company during the 4th quarter valued at about $25,000. Sierra Ocean LLC acquired a new position in Becton, Dickinson and Company in the fourth quarter valued at approximately $29,000. Picton Mahoney Asset Management boosted its holdings in shares of Becton, Dickinson and Company by 61.4% during the 4th quarter. Picton Mahoney Asset Management now owns 142 shares of the medical instruments supplier’s stock worth $32,000 after buying an additional 54 shares in the last quarter. Hopwood Financial Services Inc. acquired a new stake in shares of Becton, Dickinson and Company during the 4th quarter worth approximately $39,000. Finally, Versant Capital Management Inc increased its stake in shares of Becton, Dickinson and Company by 54.1% in the 4th quarter. Versant Capital Management Inc now owns 208 shares of the medical instruments supplier’s stock valued at $47,000 after acquiring an additional 73 shares in the last quarter. Institutional investors and hedge funds own 86.97% of the company’s stock.

Insider Activity at Becton, Dickinson and Company

In other news, EVP David Shan sold 500 shares of Becton, Dickinson and Company stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $240.00, for a total transaction of $120,000.00. Following the sale, the executive vice president now directly owns 5,741 shares in the company, valued at $1,377,840. The trade was a 8.01 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Shana Carol Neal sold 788 shares of the business’s stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $235.00, for a total transaction of $185,180.00. Following the completion of the transaction, the executive vice president now directly owns 16,201 shares in the company, valued at $3,807,235. This trade represents a 4.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 4,984 shares of company stock valued at $1,147,865. 0.36% of the stock is owned by insiders.

Analyst Ratings Changes

Several research analysts recently issued reports on BDX shares. Barclays increased their target price on shares of Becton, Dickinson and Company from $278.00 to $279.00 and gave the stock an “overweight” rating in a research note on Friday, February 14th. StockNews.com upgraded Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Wednesday. Finally, Piper Sandler upped their price target on Becton, Dickinson and Company from $275.00 to $280.00 and gave the stock an “overweight” rating in a research note on Tuesday, January 28th. Eight analysts have rated the stock with a buy rating, According to MarketBeat, Becton, Dickinson and Company presently has a consensus rating of “Buy” and a consensus price target of $278.29.

Becton, Dickinson and Company Stock Down 1.3 %

Shares of NYSE BDX opened at $226.04 on Wednesday. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.13 and a quick ratio of 0.63. The company has a 50-day moving average price of $231.38 and a 200-day moving average price of $231.62. The stock has a market capitalization of $64.90 billion, a P/E ratio of 37.55, a P/E/G ratio of 1.63 and a beta of 0.35. Becton, Dickinson and Company has a 1 year low of $218.75 and a 1 year high of $251.99.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings results on Wednesday, February 5th. The medical instruments supplier reported $3.43 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.00 by $0.43. Becton, Dickinson and Company had a return on equity of 15.74% and a net margin of 8.47%. On average, equities research analysts forecast that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company declared that its board has authorized a share buyback plan on Tuesday, January 28th that authorizes the company to repurchase 10,000,000 outstanding shares. This repurchase authorization authorizes the medical instruments supplier to repurchase shares of its stock through open market purchases. Stock repurchase plans are usually an indication that the company’s leadership believes its shares are undervalued.

Becton, Dickinson and Company Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Monday, March 31st. Investors of record on Monday, March 10th were issued a dividend of $1.04 per share. The ex-dividend date was Monday, March 10th. This represents a $4.16 annualized dividend and a yield of 1.84%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 69.10%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.